Bayshore Pharmaceuticals Recalls Metformin Hydrochloride Tablets Due to CGMP Deviations
Bayshore Pharmaceuticals is voluntarily recalling 594 bottles of Metformin Hydrochloride Extended-Release Tablets due to Current Good Manufacturing Practice (CGMP) deviations.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The source text explicitly states the agency classification is Class II. Per the rubric, if the agency's own classification is FDA Class II, the score must be at least 4 (Severe), even though no specific injuries are reported.
Plain-English summary
Bayshore Pharmaceuticals has initiated a voluntary recall of 594 bottles of Metformin Hydrochloride Extended-Release Tablets USP, 500 mg. The affected product is identified by Lot #18641 and has an expiration date of 05/2021. The tablets are manufactured by Beximco Pharmaceuticals, LTD. in Bangladesh and are distributed under NDC 76385-128-10.
The recall was initiated because of Current Good Manufacturing Practice (CGMP) deviations. The FDA has classified this recall as Class II, which indicates a situation that may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
The affected product was distributed nationwide. Consumers who have this specific lot of medication should stop using it and contact their healthcare provider or pharmacist for guidance on obtaining a replacement or alternative treatment.
The recalled product
- Product
- METFORMIN HYDROCHLORIDE (METFORMIN HYDROCHLORIDE)
- Brand
- METFORMIN HYDROCHLORIDE
- Manufacturer
- BAYSHORE PHARMACEUTICALS
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 594
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #18641
- Exp. 05/2021
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by BAYSHORE PHARMACEUTICALS under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · METFORMIN HYDROCHLORIDE
- ModerateMetformin Hydrochloride Extended-Release Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- HighMetformin Hydrochloride Extended-Release Tablets Recalled for Foreign Tablet Contamination
FDA (Drugs) · 2025-04-02
- SevereMetformin Hydrochloride Extended-Release Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2022-02-02
- HighMetformin Hydrochloride Tablets Recalled for NDMA Contamination
FDA (Drugs) · 2021-06-30
- ModerateSun Pharmaceutical Recalls Metformin Hydrochloride Tablets Due to Foreign Substance
FDA (Drugs) · 2021-05-19
Same manufacturer · BAYSHORE PHARMACEUTICALS
See all →- SevereBayshore Pharmaceuticals Recalls Metformin Hydrochloride Tablets Due to CGMP Deviations
FDA (Drugs) · 2020-09-02
Same hazard · cgmp deviations
See all →- ModerateFentanyl Citrate Injectable Solution Recall Due to cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateGlenmark Pharmaceuticals Recalls Pravastatin Sodium Tablets 80mg
FDA (Drugs) · 2025-04-16
- ModerateGlenmark Lacosamide 100mg Tablets Recalled for CGMP Deviations
FDA (Drugs) · 2025-04-16
- ModerateMigrenol Caplet Drug Recalled for CGMP Deviations
FDA (Drugs) · 2022-02-16
- ModerateDrug Recall: APAP 500 mg Phenyl HCl Tablets for CGMP Deviations
FDA (Drugs) · 2022-02-16